PharmaEssentia

Update in progress

6446.TW (Taiwan)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

PharmaEssentia Corporation is a biopharmaceutical company focused on medicine discovery and developing specialty pharmaceutical reagents, active pharmaceutical ingredients (API), and new drug candidates for markets in the Americas, Europe, Asia and Taiwan. Its product BESREMi is an interferon therapy for polycythemia vera, essential thrombocythemia, myelofibrosis and adult T-cell leukemia. The company also advances Ropeg + anti-PD-1, PEG-IL-2 (P11838), PEG-Cytokines, PD-1-IL-2v, ADCs, NY-ESO-1 TCR-T and novel TCR-T approaches for solid tumors and immunology. Founded 1990, headquartered in Taipei.

Company score

Sentiment: 0.33; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.02; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive